GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

In patients with first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors, ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

“The ASCENT-04 results build on Gilead’s aspiration of transforming the treatment of breast cancer with Trodelvy in earlier lines of therapy,” said Dietmar Berger, MD, PhD. “Together with ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Gilead Sciences’ randomised, global Phase III ASCENT-03 trial of Trodelvy (sacituzumab govitecan-hziy) has met its primary ...